• About us
• Contact

Advertisement

Organisation › Details

Novo Group (Group)

Novo A/S is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage the assets of the Foundation and actively make investments on behalf of the Foundation. Novo A/S is not a corporate strategic fund; Novo A/S invests for financial rather than strategic returns. Novo A/S is active in both Europe and North America. The Novo A/S venture investments are managed by a team of four Partners in Copenhagen, one in London and three in San Francisco. With an evergreen structure, Novo A/S annually invests approximately EUR 200 million through Novo Ventures, Novo Seeds, and Novo Growth Equity. In total Novo A/S has more than EUR 15 billion under management, which includes significant shareholdings in the independently operating and publicly listed companies Novo Nordisk A/S and Novozymes A/S. *

 

	Start	2004-09-13 existent
	Industry	venture capital
	Street	19 Tuborg Havnevej
	City	2900 Hellerup
	Tel	+45-3527-6500
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Novo Group (Group)

• [1] CMS Hasche Sigle. (3/26/24). "Press Release: CMS Advises Sellers of Cardior Pharmaceuticals on Potential Acquisition by Novo Nordisk". Munich....
• [2] Cardior Pharmaceuticals GmbH. (3/25/24). "Press Release: Novo Nordisk to Acquire Cardior Pharmaceuticals and Strengthen Pipeline in Cardiovascular Disease". Bagsværd & Hannover....
• [3] LimmaTech Biologics AG. (10/9/23). "Press Release: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections". Schlieren....
• [4] Bactolife A/S. (8/8/23). "Press Release: Bactolife Raises EUR 30 Million in Series A Financing". Copenhagen....
• [5] BioGeneration Ventures B.V.. (7/13/23). "Press Release: BioGeneration Ventures Closes BGV Fund V at €150 Million". Naarden....
• [6] Engimmune Therapeutics AG. (5/3/22). "Press Release: Engimmune Therapeutics Raises CHF 15.5 Million in Seed Financing to Develop Novel T-cell Receptor Therapeutics". Basel....
• [7] Novo Nordisk Foundation. (9/22/21). "Press Release: New Research Center Will Find Solutions to Reduce CO2 in the Atmosphere and Convert it into Valuable Raw Materials"....
• [8] Forbion Capital Partners. (9/1/21). "Press Release: Forbion Appoints Nanna Lüneborg as a General Partner". Naarden....
• [9] Cardior Pharmaceuticals GmbH. (8/25/21). "Press Release: Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease". Hanover....
• [10] Numab Therapeutics AG. (5/20/21). "Press Release: Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing". Wädenswil (Zurich)....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.